Fried Robert N 4

What Happened

• Robert N. Fried, CEO of Niagen Bioscience, Inc. (NAGE), was granted a derivative award of 503,937 shares on 2026-02-19. The reported acquisition price is $0.00 (no cash paid reported). The filing characterizes this as an award/grant (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-19; Form 4 filed: 2026-02-24.
• Amount: 503,937 shares (derivative award) at reported price $0.00; total cash paid reported = $0.
• Vesting: per footnote — one-fourth of the shares vest on each anniversary of the grant date (4-year cliff/annual vesting schedule).
• Shares owned after transaction: not disclosed in the excerpt provided.
• Timeliness: the Form 4 was filed five days after the transaction date (Form 4s are generally due within two business days); this filing may be late — check the full filing for any amendment or explanation.

Context

• This was a compensation-style award (derivative), which typically represents stock options or restricted stock units rather than an immediate market purchase. Because the reported price is $0.00, the filing doesn’t show cash outlay or immediate market value—economic value depends on grant terms (exercise price, type of award) and the company’s stock price.
• Such grants are common for executives as part of compensation and do not necessarily reflect a short-term buy/sell signal.